JAN vs WELL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: WELL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JAN and WELL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JAN and WELL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Janus Living, Inc. (NYSE: JAN) owns senior housing communities across the United States and, unusually for a healthcare REIT, takes the operating result of those communities rather than a fixed rent. Every property sits in a RIDEA structure, meaning Janus Living books resident fees and pays the operating costs, with third parties such as LCS, Sunrise Senior Living and Ciel Senior Living running the buildings under management contracts. The portfolio at June 30, 2026 was ~41 communities and ~11,420 units across ~13 states, weighted heavily toward Florida, which accounted for roughly ~51% of gross real estate assets, with Texas and Pennsylvania each near ~11%. A large slice of the portfolio is life plan communities, the entrance fee format where residents pay a substantial sum up front for the right to live on a campus that also offers assisted living and skilled care, which is why the balance sheet carries ~$699M of deferred revenue and another ~$227M of refundable entrance fees. Janus Living is externally managed by Healthpeak Investment Management, an indirect subsidiary of Healthpeak Properties (NYSE: DOC), and is headquartered in Denver.

Full JAN guide

Welltower Inc. is the largest healthcare REIT in the world, owning a portfolio of senior housing, assisted living, post-acute and long-term care, and outpatient medical real estate across the United States, the United Kingdom, and Canada. It makes money in two main ways: through its Senior Housing Operating Portfolio (SHOP), where it shares directly in the net operating income that property operators generate from residents, and through rents on triple-net leased seniors housing and care facilities plus outpatient medical buildings. Because SHOP income flows through to Welltower rather than being fixed rent, rising occupancy and room rates translate quickly into higher earnings, which is why the operating portfolio has become the company's main growth engine.

Full WELL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JAN drivers: Occupancy and rate, with almost no new supply arriving; An all-equity acquisition machine.
• WELL drivers: Aging-demographics senior-housing tailwind; Operating-portfolio NOI growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Healthpeak controls about ~69.7% of the voting power and also supplies the external manager, whose fee is tied to the gross book value of investments acquired, which rewards balance sheet growth whether or not it earns its cost of capital. For WELL, welltower's share price is sensitive to interest rates, since higher rates raise borrowing costs and make REIT dividend yields less competitive against bonds.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JAN if you believe its drivers more; WELL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JAN and WELL guides.

JAN. The reported price to earnings ratio for JAN runs into the hundreds and should be ignored, because first half GAAP income was dominated by a ~$46.3M gain on taking control of a joint venture and offset by ~$22.8M of IPO and transaction costs. FFO as Adjusted is the measure the company guides on, and at roughly ~$30 per share against guidance of ~$0.95 to ~$0.98 the stock changes hands near ~31 times, a premium to most diversified healthcare REITs. The ~$0.57 annualized dividend works out to a yield under ~2%, low for a REIT and a sign that the market is paying for growth here rather than income.

WELL. Healthcare REITs are valued on funds from operations (FFO) rather than EPS, because standard net income is weighed down by large non-cash depreciation charges on real estate. For Welltower the most important operating metric is same-store NOI growth in the Senior Housing Operating Portfolio, since that captures how much extra income the company earns as occupancy and room rates rise. Welltower trades at a notably higher FFO multiple, and a lower dividend yield, than most healthcare REIT peers, reflecting the market's confidence in its senior-housing growth, its scale, and its balance sheet; that premium is part of the investment case and part of the risk.

Headline figures (approximate, August 2026): JAN shows revenue (ttm) ~$723M, q2 2026 revenue ~$216M, up ~45% year over year, ffo as adjusted (q2 2026) ~$0.24 per share, up ~40%, 2026 guidance, ffo as adjusted ~$0.95 to ~$0.98 per share; WELL shows normalized ffo per share (2025) $5.29 (+~22.5%), 2026 normalized ffo guidance $6.09 to $6.25, shop same-store noi growth (q4 2025) ~20.4% YoY, revenue (2025) ~$10.84 billion (+~36%).

JAN and WELL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JAN and WELL exposure against your real portfolio. It is not an investment adviser.